Enhanced yield and cannabinoid production of homogenous medical marijuana plants

该提案中指出的这项研究将产生与快速发展的大麻产业相关的关键知识，以提供具有一致大麻素浓度的高质量植物材料。 该项目将解决三个知识差距：1）基于遗传和代谢组学标记快速识别大麻品种，以进行质量控制; 2）稳定流行大麻品种的遗传学，并开发通过种子繁殖这些品系的方法; 3）使用微生物信号化合物改变产量，大麻素浓度和植物抗病性。 这项研究很重要，因为大麻生产商必须能够种植一致的医用植物材料，以便在将大麻素作为药用级药物处方时提供可靠的大麻素剂量（数量和成分）。 此外，必须解决植物对白粉病的抗病性，因为目前很少有注册的控制产品，导致产量和质量显着下降;本研究项目中提出的方法也不会在用于人类消费的鲜花上留下化学痕迹。 这项研究对1）大麻生产商，2）临床医生和3）患者都很重要。 大麻生产商将受益于产量损失的减少;临床医生将受益于更广泛的一致的大麻产品，这些产品可以在临床试验中进行评估，用于治疗各种疾病;患者将受益于改善获得一系列高质量大麻药品的机会。 该项目的预期成果是：1）基于遗传学和代谢物的大麻菌株的快速和廉价鉴定系统，2）生产遗传上相同的雌性大麻种子的方法，以及3）调节大麻素浓度和组成以及控制大麻白粉病的新策略。 工业合作伙伴RavenQuest Biomed将通过改进的生产方法和一致且特征良好的植物遗传学受益。 加拿大将受益于利用这些知识，将自己定位为高质量医用大麻生产的世界领导者，增加大麻销售的税收。

This research indicated in this proposal will produce critical knowledge relevant for the rapidly-expanding Cannabis industry, to provide high quality plant material with consistent cannabinoid concentrations. The project will address three knowledge gaps: 1) identifying Cannabis cultivars quickly, based on genetic and metabolomics markers, for quality control purposes; 2) stabilizing genetics of popular Cannabis cultivars and developing methods for propagating these lines via seeds; 3) altering yield, cannabinoid concentration and plant disease resistance using a microbial signal compound. This research is important because Cannabis producers must be able to grow consistent plant material for medical use in order to provide reliable doses (amount and composition) of cannabinoids when it is prescribed as a pharmaceutical-grade drug. Furthermore, plant disease resistance against powdery mildew must be addressed, since currently few registered control products are available, resulting in significant yield and quality reductions; the proposed method in this research project would also not leave chemical traces on flowers that will be used for human consumption. This research is important to 1) Cannabis producers, 2) clinicians and 3) patients. Cannabis producers will benefit from reduced yield losses; clinicians will benefit from a wider range of consistent Cannabis products that can be evaluated in clinical trials for treatment of a variety of medical conditions; patients will benefit from improved access to a range of high-quality Cannabis-based pharmaceutical products. The anticipated outcomes of this project are 1) a rapid and inexpensive identification system for Cannabis strains based on genetics and metabolites, 2) a method for producing genetically identical female Cannabis seeds, and 3) a novel strategy for regulating cannabinoid concentrations and composition and powdery mildew control in Cannabis. RavenQuest Biomed, the industrial partner, will benefit through improved production methods and consistent and well characterized plant genetics. Canada will benefit by using this knowledge to position itself as a world leader in production of high-quality medical Cannabis, increased tax revenues from Cannabis sales.